Metastatic NSCLC
Bevacizumab Beyond Progression in Metastatic NSCLC
... 36.4% with a median duration of response of 6 months. When we look to the median follow up duration from the time of initial diagnosis till loss of follow up or death, we find a median duration of 23 months, which can ...
6
Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients
... advanced NSCLC may most likely benefit from advanced therapy lines when they experienced disease control after first- and second-line treatments and have a favorable perform- ance status ...
9
Favorable Response of Advanced Superior Sulcus Non-Small Cell Lung Carcinoma to Gefitinib for 11 years complicated by Interval Development of Small Cell Carcinoma of the Lung.
... with metastatic NSCLC that was EGFR mutation–positive and previously ...had metastatic, EGFR-positive NSCLC and received first-line treatment with ...
10
<p>A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation</p>
... This review mainly analyzes the quality of articles pub- lished since 2000 on health economic evaluations (HEEs) of fi rst-line targeted treatments (afatinib, ge fi tinib, erlotinib and osimertinib) used in the treatment ...
12
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
... stable metastatic NSCLC was assessed for five European countries (the United Kingdom, Germany, France, Spain, and Italy) with an area-under-the-curve model consisting of three health states ...
7
Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
... of metastatic non-small cell lung cancer (NSCLC) has dramatically changed the prognosis of selected ...oncogene-addicted metastatic NSCLC harbouring an epidermal growth factor receptor (EGFR) ...
12
mRNA expression levels and genetic status of genes involved in the EGFR and NF κB pathways in metastatic non small cell lung cancer patients
... 60 metastatic NSCLC patients who were vis- ited at the Medical Oncology Service of the USP Dexeus University Institute (Barcelona, Spain) were assessed for mRNA expression of eleven genes (CYLD, A20, EZH2, ...
9
<p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies</p>
... for NSCLC, regardless of whether PD-L1 expression is high or ...III NSCLC who are not candidates for surgical resection or definitive chemor- adiation or metastatic NSCLC with PD-L1 TPS ≥1% ...
17
Non small cell lung cancer with metastasis to thigh muscle and mandible: two case reports
... solitary metastatic bone lesion or of muscle metastasis in pa- tients who are oligometastatic and plurimetastatic could be considered as therapeutic options, palliative radiation therapy was offered to our ...
5
Crizotinib in non small cell lung cancer
... tatic NSCLC, the tumor which has a genetic defect on chromosome 2, resulting in the fusion of two genes, ALK and EML4 (echinoderm microtubule-associated protein- like 4) ...and metastatic NSCLC ...
5
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
... In this multicenter, open-label study (NCT02501096), patients with measurable, confirmed metastatic NSCLC and ECOG performance status ≤ 1 received lenvatinib (20 mg/day orally) and pembrolizumab (200 mg ...
11
Health state utilities for non small cell lung cancer
... The study faces one significant potential limitation. It would have been possible to collect these data from patients with the relevant disease using a generic measure such as the EQ-5D. People could have completed the ...
15
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
... in NSCLC. Thus far, erlotinib indications in NSCLC include all subgroups of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy ...that NSCLC patients ...
14
Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
... Although pancreatic cancer with double primary tumors seems to be a rare occurrence, data reports that this event raises an incidence variable from 0.75% to 20.0% [2-5]. In particular, in a study evaluating the incidence ...
10
Systemic therapy in patients with NSCLC with brain metastasis: the emerging role of immunotherapy
... 12. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Ba- hary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner ...
8
Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients
... 60 NSCLC and 40 breast cancer ...In NSCLC, FRα expression was shown in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas ...of NSCLC patients showed concordant FRα expression as their ...
13
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
... Three other studies addressed the cost-effectiveness of treatments including erlotinib [24-26]. The objective of a study by Chouaid et al. [24] was to assess the cost- effectiveness of erlotinib followed by chemotherapy ...
11
Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
... Abstract: Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard first- line chemotherapy ...
10
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
... Immunotherapy of cancer has entered a new and exciting phase because of the discovery of checkpoint receptor inhibitors, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and, more recently, programmed death-1 (PD1) ...
12
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
... rearranged NSCLC? Fast-forward a decade from now, it is predicted that a myriad of systemic therapies will be avail- able at the dispense of clinicians, including selective ALK inhibitors, immunomodulatory agents, ...
8